The Street's story is a two-horse race. Two companies, two franchises, a duopoly minting money. It is a clean narrative, and on revenue today it is roughly right. The patent record says the next chapter may be messier.
Here's the single fact that undercuts the duopoly framing: the 2023 incretin-peptide filings are crowded, and they come from all over. Sanofi's publication US20230103631A1 stakes out peptides as selective GIP receptor agonists. Viking Therapeutics' grant US11744873B2 covers compositions for metabolic and liver disorders. These are not the incumbents.
Acknowledge the bull case for the duopoly: incumbency in this market is real. Manufacturing peptides at scale is hard, the brands are entrenched, and the surrounding formulation patents are thick. A new molecule on paper is a long way from a prescription.
But read the filing stream and the steelman wobbles. Publication US20230346961A1 covers GLP-1 and GIP receptor co-agonists from yet another group. When this many independent parties are filing on the same dual- and triple-agonist territory, the barrier to a differentiated entrant is lower than 'two horses' implies.
The contrarian caution cuts the other way too, though. A patent application is not a drug. A large fraction of these filings are early publications that will never clear a Phase 3 readout. Counting them as competition is as wrong as ignoring them.
So the honest reality check: the GLP-1 race is not a two-company story, and the 2023 patent map proves it — but crowding on paper is intent, not arrival. The cliff for the incumbents is real; it is just further out, and lumpier, than either the duopoly bulls or the disruption bears want to admit.